Clinical Trials Sponsored by Korea Otsuka Pharmaceutical Co., Ltd.

Total 3902 results

Otsuka Pharmaceutical Co., Ltd.

Completed

A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia

Schizophrenia

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Study of OPA-15406 Ointment in Patients With Atopic Dermatitis

Atopic Dermatitis

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients

Heart Failure

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia

Schizophrenia

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]

Autosomal Dominant Polycystic Kidney Disease （ADPKD)

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Trial to Determine the Safety, Pharmacokinetics, and Efficacy of OPC-108459 Administered as a Single Intravenous Dose to Patients With Paroxysmal or Persistent Atrial Fibrillation (AF)

Atrial Fibrillation

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]

Autosomal Dominant Polycystic Kidney Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder

Major Depressive Disorder

Australia, Taiwan, Malaysia, Korea, Republic of, Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder

Autistic Disorder

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia

Schizophrenia

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Short Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder

Autistic Disorder

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 1,Open -Label Study to Assess the Absorption, Metabolism and Excretion of 14C-OPS-2071 Following a Single Oral Dose to Healthy Male Japanese Subjects

Bacterial Enteritis

United Kingdom
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male Subjects

Atopic Dermatitis

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Trial to Explore Symptomatic Therapy for Application Site Reaction to SPM962 in Healthy Subject

Healthy

Korea, Republic of
Otsuka Pharmaceutical Co., Ltd.

Completed

A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) Patients

Idiopathic Restless Legs Syndrome

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients

Parkinson's Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Long Term Administration Study of OPC-12759 Ophthalmic Suspension

Dry Eye Syndromes

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode

Bipolar I Disorder

Taiwan, Korea, Republic of, Japan, China
Otsuka Pharmaceutical Co., Ltd.

Completed

A Multicenter, Investigative Study of the Safety and Efficacy of Extended Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode

Bipolar I Disorder

Taiwan, Korea, Republic of, Japan, China
Otsuka Pharmaceutical Co., Ltd.

Completed

Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder

Major Depressive Disorder

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)

Edema, Cardiac

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis

Pain Due to Osteoporosis

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Late Phase 2 Study of OPC-12759 Ophthalmic Suspension

Dry Eye Syndromes

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)

Cerebral Infarction

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Safety and Pharmacokinetic Study of C13-URA in Healthy Volunteers

Gastroparesis

United States
Seoul National University Hospital
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease (IMPACTonIMT)

Hyperlipidemias

Korea, Republic of
Chonbuk National University Hospital
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety of Aripiprazole in First Episode Psychosis

First Episode Psychosis

Korea, Republic of
Gyeongsang National University Hospital
Korea Otsuka Pharmaceutical Co., Ltd.

Unknown

Cilostazol and Endothelial Progenitor Cell (EPISODE)

Myocardial Infarction, Acute
Seoul National University Hospital
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders

Bipolar Disorders | Metabolic Complication

Korea, Republic of
Chonnam National University Hospital
Korea Otsuka Pharmaceutical Co., Ltd.

Unknown

Busulfan and Melphalan Conditioning in Multiple Myeloma

Multiple Myeloma

Korea, Republic of
Seoul National University Hospital
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia

Schizophrenia

Korea, Republic of
Otsuka Pharmaceutical, Inc., Philippines
Otsuka Pharmaceutical Co., Ltd.

Terminated

Tiotropium + Procaterol vs Tiotropium + Placebo in COPD Patients

Pulmonary Disease, Chronic Obstructive

Philippines
Thai Otsuka Pharmaceutical Co., Ltd.

Completed

Study of Arginine Free IED in Critically Ill Patients. (ROSIED)

Critical Illness

Thailand
Otsuka Pharmaceutical Co., Ltd.
Covance

Completed

Phase 2 Study to Evaluate the Preliminary Performance of the C13-URA Breath Test Kit in Dyspeptic Subjects

Dyspeptic Subjects

United States
Korea University
Taiwan Otsuka Pharm. Co., Ltd; Korea OIAA

Unknown

Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder

Major Depressive Disorder

Korea, Republic of, Taiwan
Chonbuk National University Hospital
AstraZeneca; Sanofi-Synthelabo; Janssen Korea, Ltd., Korea; Korea Otsuka Pharmaceutical...

Completed

Different Safety Profile of Risperidone and Paliperidone Extended-release

Schizophrenia

Korea, Republic of
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Withdrawn

Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability

Major Depressive Disorder and Irritability

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment

MDD

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy

Major Depressive Disorder (MDD)

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Outcomes in MEasurement-Based Treatment (COMET)

Depressive Disorder, Major
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

"SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia

Inappropriate ADH Syndrome | Water Intoxication | Hyponatremias | Water-Electrolyte Imbalances

United States
Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Development & Commercialization, Inc.

Recruiting

Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia

Acute Schizophrenia

Japan
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity

Schizophrenia With Impulsivity

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (TEMPO 2:4)

Polycystic Kidney, Autosomal Dominant

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (TEMPO3:4)

Polycystic Kidney Disease, Autosomal Dominant

United States, Belgium, United Kingdom, Russian Federation, France, Australia, Netherlands, Italy, Japan, Denmark, Romania, Poland, Canada, Argentina, Germany
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms

Anxiety | Major Depressive Disorder

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia

Schizophrenia
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease (OVERTURE)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States, Argentina, Australia, Belgium, Brazil, Canada, Czech Republic, France, Germany, Italy, Japan, Netherlands, Norway, Poland, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia

Schizophrenia

United States

Clinical Trials Sponsored by Korea Otsuka Pharmaceutical Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations